Molecular editing, rooted in synthetic chemistry, has emerged as a powerful tool for structure optimization in medicinal chemistry but remains underutilized in targeted protein degradation. Here, we demonstrate the utility of molecular editing by repurposing the NSD2 degrader LLC0424 with GSPT1 neosubstrate engagement to generate two structurally analogous molecules with divergent modes of action: 424-ND, a PROTAC selective for NSD2, and 424-GD, a selective GSPT1 molecular glue. 424-ND drove NSD2 degradation selectively in a CRBN- and proteasome-dependent manner and functionally suppressed androgen receptor (AR) signaling in prostate cancer cells. 424-GD induced selective degradation of GSPT1 and robustly upregulated the integrated stress response markers ATF4 and ATF3. Biolayer interferometry revealed distinct ternary complex cooperativity profiles in the presence of NSD2 or GSPT1, which directly correlate with the observed biased degradation activity. Further molecular dynamics and metadynamics simulations showed that the compounds adopt distinct low-energy conformational ensembles with different spatial orientations, likely underlying their divergent cooperativity and selectivity. These findings not only deliver highly selective chemical probes for NSD2 and GSPT1 but also demonstrate that molecular editing enables precision control over target selectivity, providing a generalizable strategy to tune selectivity in targeted protein degradation. Table of Contents Graphic
Lysine-specific demethylase 1 (LSD1, KDM1A) drives oncogenic progression in acute myeloid leukemia (AML) through both catalytic histone demethylation and non-catalytic scaffolding interactions with oncogenic transcription factors. Conventional LSD1 inhibitors either suffer from severe off-target toxicity or fail to blo...
A “2-in-1” PROTAC design strategy for developing more compact HDAC8 degraders by integrating the CRBN-recruiting ligand into the capping group of an HDAC8 warhead, thereby enabling a single structural motif to engage both HDAC8 and CRBN.
Yi Liu, Nikee Awasthee, Yufeng Xiao et al.· Journal of Medicinal Chemist...· 0 citations
Repurposing the clinical-stage Bcl-xL BH3 mimetic A-1331852 is identified as a potent PTP1B inhibitor demonstrating a selectivity margin of at least 50-fold over TCPTP, highlighting A-1331852 as a promising starting point for developing PTP1B inhibitors designed to exploit transient, substrate-induced binding states.
Nathaly Vasquez-Martínez, Alejandro Sosa-Peinado, Francisco Cortés-Benítez et al.· Bioorganic & Medicinal Chemi...· 0 citations
This study establishes C367 as a druggable covalent site in the historically challenging STAT3 DBD, validates FEP-guided optimization of covalent inhibitors, and identifies compound 16 as a promising next-generation lead with a superior drug-like profile for targeting STAT3-dependent cancers.
Yang-Ping Deng, H. Bian, Feng-Yuan Zhang et al.· Journal of Chemical Informat...· 0 citations
The first-ever domain-selective covalent inhibitor of BET BD2 domains by installing an epoxide warhead onto the scaffold of ABBV-744 is reported, establishing for the first time a novel targeted covalent inhibition (TCI) strategy that engages two weakly nucleophilic residues within a single bromodomain.
Ji-Bo Kang, Xuan Wang, Hong Zhang et al.· Angewandte Chemie· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.